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Two functions of p53 are undisputed. Biologically, p53 is a potent tumor suppressor, whereas biochemically,
it is a robust transcriptional activator of numerous target genes. Are these biological and biochemical func-
tions of p53 related? The surprising answer, recently reported by Brady et al. (2011) in Cell, is minimally.More than 30 years after its discovery as
an erroneously assigned oncoprotein—
and more than 20 years after its recogni-
tion as a potent tumor suppressor protein
(Levine and Oren, 2009)—p53 retains the
ability to surprise. Years of p53 research
revealed an array of interrelated biological
functions. These include regulation of
cell-cycle progression, apoptosis, and
cellular senescence, which are thought
to contribute to p53’s vital function as a
suppressor of malignant tumorigenesis.
In parallel, years of research have uncov-
ered an assortment of p53 biochemical
activities. These include participation in
the assembly of DNA repair complexes,
regulation of mitochondrial function, and,
perhaps most intensively studied, se-
quence-specific DNA binding and subse-
quent transactivation of gene expression.
Yet, despite abundant effort, questions
remain regarding which biochemical ac-
tivities of p53 are important for which bio-
logical functions.
Two p53 functions have received wide-
spread attention: orchestration of cellular
responses to acute DNA damage and
tumor suppression. In response to DNA
damage, p53 transiently delays cell-cycle
progression, presumably to facilitate
repair, or induces cell death (apoptosis)
or permanent cell-cycle arrest (cellular
senescence) if the damage is severe
or irreparable. These responses were
thought to suppress cancer by eliminating
or preventing the propagation of cells with
genomic damage and hence the danger
of developing oncogenic mutations. In-
deed, p53 null mice are highly prone to
developing spontaneous and damage-
induced tumors. However, early parsing
of p53’s activities in mouse models
yielded surprising results (Tuma, 2004).
First, mice in which wild-type p53 was
replaced by a mutant protein that caninduce cell-cycle arrest, but not ap-
optosis, in response to acute damage or
stress retained substantial protection
from spontaneous tumorigenesis (Liu
et al., 2004). This finding suggested that
cell-cycle arrest is more important for
tumor suppression than the apoptotic
response to damage. Second, analysis
of mice carrying a p53 protein that can
be switched from functional to inactive
states in vivo showed that the rapid p53-
mediated response to acute DNA damage
is less important for tumor suppression
than the sustained expression of a func-
tional p53 protein, which presumably
limits the proliferation of cells harboring
oncogenic mutations (Christophorou
et al., 2006). Likewise, conditional inacti-
vation of p53 after acute DNA damage
showed that sustained, rather than imme-
diate, p53 activity is crucial for preventing
the emergence of cancer (Hinkal et al.,
2009). How then are the acute and sus-
tained functions of p53 determined, and
by what mechanisms do sustained p53
activity suppress tumorigenesis?
In a recent study published in Cell,
Brady et al. (2011) now answer these
questions by dissecting a well-studied
biochemical function of p53: transactiva-
tion. Two separate transactivation do-
mains (TADs), both in the N-terminal
region of p53, determine this activity.
Brady et al. (2011) generated mice that
carry homozygous mutations in either or
both TADs (TAD1, inactivated by amino
acid substitutions at residues 25 and 26,
and TAD2, inactivated by substitutions
at residues 53 and 54).
Mouse embryonic fibroblasts (MEFs)
and mice carrying mutations in both
TADs behaved much like p53 null MEFs
and mice (Figure 1). The MEFs expressed
very few p53 target genes, failed to sen-
esce in response to an H-Ras oncogene,Developmental Celand failed to arrest in G1 after acute
exposure to ionizing radiation (IR). More-
over, cells in radiosensitive tissues failed
to undergo apoptosis after IR exposure
in vivo. Not surprising, when combined
with a mouse model of K-Ras-induced
lung cancer, animals lacking both TADs
developed many lung tumors. These find-
ings confirm the importance of trans-
activation for both rapid p53-mediated
responses and the sustained p53 func-
tion that is needed for efficient tumor
suppression.
In contrast to double TAD mutants,
TAD2 single mutants displayed near-
wild-type behavior, whereas TAD1 mu-
tants showed surprising phenotypes (Fig-
ure 1). In response to oncogenic H-Ras,
TAD1 mutant MEFs expressed only
a small subset of p53 target genes. None-
theless, they readily underwent senes-
cence, yet failed to arrest in G1 or
undergo apoptosis after IR exposure.
Remarkably, TAD1 mutant mice were
substantially protected from K-Ras-
induced lung tumors. Thus, full transacti-
vation activity was essential for the cell-
cycle arrest and apoptotic responses to
acute damage but not for the senescence
response or tumor suppression. That is,
only a small number of p53 target genes
are required for senescence and tumor
suppression—much smaller than the
number required for acute p53 responses.
In a remarkably successful extension of
this finding, Brady et al. (2011) used the
restricted number of genes induced by
TAD1 mutant p53 to profile human and
mouse tumors. Loss of p53 tumor sup-
pressor activity, as measured by the
downregulated expression of 130 genes
induced by wild-type and single TAD
mutant p53 proteins, distinguished p53
wild-type from p53 mutant human breast
cancers; low tumor suppressor activityl 20, May 17, 2011 ª2011 Elsevier Inc. 573
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Figure 1. Activities of p53 Mutants
Wild-type p53 (left) has two intact transactivation domains (TAD1, TAD2),
which induce a full complement of target genes in response to oncogene
signaling (Ras). Cells with wild-type p53 respond to Ras by undergoing senes-
cence and respond to ionizing radiation (IR) by undergoing cell-cycle (cc)
arrest or apoptosis. Mice with wild-type p53 show high tumor suppressor
(TS) activity. Cells and mice with mutations that inactivate either (center) or
both (right) TADs (indicated by X) display phenotypes that range from near-
wild-type (TAD2 inactive) to near null (both TADs inactive). The phenotypes
of cells and mice with inactive TAD1 identify a small subset of target genes
that are essential for senescence and tumor suppression.
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Previewscorrelated with poor patient
survival. Moreover, the 130
gene signature contained
a subset of 14 genes that
were consistently downregu-
lated in numerous types of
human and mouse cancers.
Finally, overexpression of
certain of the 14 genes sup-
pressed the proliferation of
p53 null/oncogenic H-Ras
expressing MEFs. Con-
versely, RNAi-mediated de-
pletion of a subset of these
genes stimulated tumor
formation by partially trans-
formed p53 wild-type MEFs.
The identification of
a network of p53 target genes
that is crucial and selective
for tumor suppression is
a milestone that opens many
doors and poses many ques-
tions. How tightly is the abilityof p53 to induce senescence linked to its
ability to suppress tumorigenesis in the
setting of oncogene signaling, and how
much overlap exists between the mecha-
nisms by which p53 executes both these
processes? What determines the selec-
tivity of target gene induction in response
to acute damage or stress versus onco-
gene signaling? Brady et al. (2011) specu-
late that the discrimination may be gov-
erned by protein-protein interactions
between p53 and as-yet-unknown
binding partners. Given the expanding574 Developmental Cell 20, May 17, 2011 ª2evidence that p53 can regulate metabolic
pathways (Gottlieb and Vousden, 2010),
target gene selectivity might also be
determined by metabolites that are
produced after acute damage or in
response to oncogenic signals. What
roles if any do the p53 target genes that
are selectively induced during tumor
suppression play in other important bio-
logical processes? Given the growing
(albeit still tenuous) links between cellular
senescence and aging phenotypes, and
the antagonism between tumor suppres-011 Elsevier Inc.sion and aging in some
contexts (Rodier and Campisi,
2011), do tumor-suppressive
p53 target genes also play
roles in organismal aging and
longevity? The discovery by
Brady et al. (2011) that
a surprisingly limited number
of genes determine p53’s
ability to induce senescence
and protect from cancer will
greatly facilitate research to
answer these questions.
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